Lucid Diagnostics Announces Upcoming Business Update Conference Call
Lucid Diagnostics Inc. is set to host a significant conference call and webcast designed to update investors and stakeholders on the company's business strategies and financial performance. This event will take place on Wednesday at 8:30 AM Eastern Time, offering an insightful look into the operations and growth plans of Lucid Diagnostics.
Details of the Conference Call
During this anticipated call, Lucid's Chairman and CEO, Lishan Aklog, M.D., will provide a comprehensive overview of the company’s initiatives and growth trajectory. This is an excellent opportunity for investors to gain insight directly from the leadership regarding the company's direction and objectives. Additionally, Dennis McGrath, the Chief Financial Officer, will share the financial results for the first quarter of 2025, delivering crucial information on the company's fiscal health and performance metrics.
How to Join the Webcast
The live webcast will be accessible through the investor relations section of Lucid Diagnostics’ website. Callers in the U.S. can participate by dialing 1-800-836-8184, while international attendees are encouraged to call 1-646-357-8785. Participants will be asked to reference the conference call name "Lucid Diagnostics Business Update" to ensure they are included in the discussion.
Information on Replay Availability
For those unable to attend the live event, a replay will be provided for 30 days, allowing stakeholders to catch up on any information shared during the call. This availability reinforces the company’s commitment to transparency and communication with its investors.
Understanding Lucid Diagnostics
Lucid Diagnostics Inc. stands at the forefront of cancer prevention diagnostics, focusing particularly on patients suffering from gastroesophageal reflux disease (GERD), often linked to esophageal precancer and cancer risks. Through innovative testing methods, including the EsoGuard Esophageal DNA Test, Lucid aims to enhance early detection and ultimately reduce cancer mortality. Their EsoCheck Esophageal Cell Collection Device complements these efforts by facilitating noninvasive testing aimed at identifying at-risk patients.
Advancing Cancer Detection
As a subsidiary of PAVmed Inc., Lucid Diagnostics is committed to developing tools that can provide significant benefits to health practitioners and patients alike. Their pioneering approach to cancer diagnostics enables clinical professionals to enhance patient care through proactive management of potential health threats associated with GERD, exemplifying the importance of technological advancements in prevention-centric healthcare.
Frequently Asked Questions
What is the date and time of the conference call?
The conference call is scheduled for Wednesday at 8:30 AM Eastern Time.
Who will lead the call?
The call will be led by Lishan Aklog, M.D., the Chairman and CEO of Lucid Diagnostics, along with CFO Dennis McGrath.
Where can I access the call?
The call can be accessed via a dedicated dial-in number, with options for both U.S. and international listeners.
Is there a replay available after the call?
Yes, a replay of the conference call will be available for 30 days on the investor relations section of Lucid Diagnostics' website.
What is Lucid Diagnostics' area of focus?
Lucid Diagnostics specializes in cancer prevention medical diagnostics, targeting patients at risk for esophageal conditions resulting from GERD.
